AbbVie Gains EU Committee Backing for MAVIRET Expansion into Acute Hepatitis C Indication

A positive CHMP opinion for AbbVie's MAVIRET in acute hepatitis C positions the drug for formal European Commission approval, and signals a replicable pathway for manufacturers pursuing indication expansion on already-licensed products. If the Commission endorses the committee's recommendation, MAVIRET will be among a narrow set of therapies in the EU carrying a label covering both acute and chronic HCV infection.

The current MAVIRET authorisation covers chronic hepatitis C in adults and paediatric patients aged three and older. The proposed expansion targets acute HCV, a phase of infection where early intervention can prevent progression to chronic disease and reduce onward transmission. For regulatory affairs leads, the dossier strategy here reflects a disciplined post-approval change management approach: leveraging an established safety and efficacy dataset to support a new indication rather than initiating a standalone development programme.

The clinical rationale aligns with evolving treatment guidelines that favour earlier intervention in HCV management. Acute hepatitis C is frequently asymptomatic and underdiagnosed, which has historically limited the evidence base for acute-phase treatment approvals. A label that explicitly covers acute infection gives prescribers and health systems a clearer regulatory anchor for early treatment decisions, with downstream implications for HCV elimination targets set by the World Health Organization.

From a post-approval lifecycle perspective, the CHMP opinion illustrates how a well-maintained regulatory file can support incremental label work without the full burden of a new marketing authorisation application. QA and regulatory teams managing similar assets should note the documentation requirements under ICH Q10 for change control and the variation procedures applicable under EU centralised procedure rules, both of which bear directly on the speed and completeness of indication expansion submissions.

The European Commission typically issues a final decision within 67 days of a CHMP opinion, making a formal approval likely before the end of Q3 2026.

Source: Indian Pharma Post via Media4Growth, 24 May 2026.